Literature DB >> 9345438

Clinical and magnetic resonance imaging predictors of disability in primary and secondary progressive multiple sclerosis.

N A Losseff1, D P Kingsley, W I McDonald, D H Miller, A J Thompson.   

Abstract

The role of magnetic resonance imaging (MRI) in predicting disability in multiple sclerosis (MS) remains unclear. In this study 21 patients with primary and secondary progressive MS were reviewed 5 years following a serial MRI study of 6 months duration. In the secondary progressive group (n = 11) there was a significant relationship between the occurrence of enhancing lesions and clinical relapses during the initial 6 months and increase in disability 5 years later. For both groups change in disability over the initial study period was predictive of outcome. These results suggest that the presence and frequency of gadolinium enhancement (a marker of inflammation) and changes in disability over a short period are predictive of future deterioration in progressive patients.

Entities:  

Mesh:

Year:  1996        PMID: 9345438

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  12 in total

1.  Three subsequent single doses of gadolinium chelate for brain MR imaging in multiple sclerosis.

Authors:  Francesco Sardanelli; Andrea Iozzelli; Caterina Losacco; Alessandra Murialdo; Massimo Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2003-04       Impact factor: 3.825

2.  Overcoming the clinical-MR imaging paradox of multiple sclerosis: MR imaging data assessed with a random forest approach.

Authors:  K Kacar; M A Rocca; M Copetti; S Sala; S Mesaros; T Stosic Opincal; D Caputo; M Absinta; J Drulovic; V S Kostic; G Comi; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2011-11-11       Impact factor: 3.825

Review 3.  Magnetic resonance in monitoring the natural history of multiple sclerosis and the effects of treatment.

Authors:  M Filippi; M Rovaris; G Comi
Journal:  Ital J Neurol Sci       Date:  1996-12

4.  Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis.

Authors:  T Koudriavtseva; A J Thompson; M Fiorelli; C Gasperini; S Bastianello; A Bozzao; A Paolillo; A Pisani; S Galgani; C Pozzilli
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

Review 5.  The current state-of-the-art of spinal cord imaging: applications.

Authors:  C A Wheeler-Kingshott; P W Stroman; J M Schwab; M Bacon; R Bosma; J Brooks; D W Cadotte; T Carlstedt; O Ciccarelli; J Cohen-Adad; A Curt; N Evangelou; M G Fehlings; M Filippi; B J Kelley; S Kollias; A Mackay; C A Porro; S Smith; S M Strittmatter; P Summers; A J Thompson; I Tracey
Journal:  Neuroimage       Date:  2013-07-14       Impact factor: 6.556

6.  Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis.

Authors:  Marco Rovaris; Giancarlo Comi; David Ladkani; Jerry S Wolinsky; Massimo Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2003-01       Impact factor: 3.825

Review 7.  MRI measures of neurodegeneration in multiple sclerosis: implications for disability, disease monitoring, and treatment.

Authors:  Massimo Filippi
Journal:  J Neurol       Date:  2014-04-11       Impact factor: 4.849

8.  The value of chemical fat-saturation pulse added to T1-weighted spin-echo sequence in evaluating gadolinium-enhancing brain lesions in multiple sclerosis.

Authors:  F Sardanelli; S Schiavoni; A Iozzelli; A Fausto; A Aliprandi; G L Mancardi; M Filippi
Journal:  Radiol Med       Date:  2007-12-13       Impact factor: 3.469

Review 9.  Nuclear magnetic resonance monitoring of treatment and prediction of outcome in multiple sclerosis.

Authors:  D H Miller; A J Thompson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

10.  Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis.

Authors:  C M Dalton; P A Brex; R Jenkins; N C Fox; K A Miszkiel; W R Crum; J I O'Riordan; G T Plant; A J Thompson; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-08       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.